We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+18.15%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.53B
AUM Growth
-$36.8M
Cap. Flow
-$162M
Cap. Flow %
-10.58%
Top 10 Hldgs %
64.78%
Holding
69
New
17
Increased
8
Reduced
13
Closed
17

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$125M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$49M
3
IDXX icon
Idexx Laboratories
IDXX
+$33.9M
4
EXEL icon
Exelixis
EXEL
+$33.3M
5
BSX icon
Boston Scientific
BSX
+$31.8M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$84M
2
LLY icon
Eli Lilly
LLY
+$47.1M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$44.6M
4
BIIB icon
Biogen
BIIB
+$36.9M
5
MRK icon
Merck
MRK
+$35.7M

Sector Composition

Rank Sector Weight
1 Healthcare 98.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
YMAB
26
DELISTED
Y-mAbs Therapeutics
YMAB
$14.9M 0.98%
2,194,278
– –
RVMD icon
27
Revolution Medicines
RVMD
$40.2B
$13.9M 0.91%
520,377
+336,539
+183% +$8.26M
AXSM icon
28
Axsome Therapeutics
AXSM
$12.4B
$12.9M 0.84%
179,242
+58,346
+48% +$4.3M
VIR icon
29
Vir Biotechnology
VIR
$1.47B
$12M 0.78%
488,117
-169,442
-26% -$4.26M
PTCT icon
30
PTC Therapeutics
PTCT
$6.37B
$10.6M 0.69%
260,443
-256,652
-50% -$12.6M
MRNS
31
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$10.5M 0.68%
962,619
-237,770
-20% -$2.04M
GRTX
32
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$9.62M 0.63%
3,083,712
– –
REPL icon
33
Replimune Group
REPL
$814M
$8.1M 0.53%
+348,889
New +$6.82M
AGEN
34
Agenus
AGEN
$249M
$7.85M 0.51%
245,457
-81,003
-25% -$2.59M
VIR icon
35
PUT
Vir Biotechnology
VIR
$1.47B
$7.36M 0.48%
+300,000
New +$7.53M
CLDX icon
36
Celldex Therapeutics
CLDX
$2.77B
$6.71M 0.44%
197,758
-221,639
-53% -$7.47M
DYN icon
37
Dyne Therapeutics
DYN
$4.04B
$4.96M 0.33%
+441,048
New +$5.2M
NXTC icon
38
NextCure
NXTC
$17.3M
$4.81M 0.32%
222,655
– –
NCNA
39
NuCana
NCNA
$5.37M
$4.42M 0.29%
1,120
– –
BOLT icon
40
Bolt Biotherapeutics
BOLT
$7.36M
$3.53M 0.23%
137,722
– –
MRNS
41
CALL
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$2.17M 0.14%
+200,000
New +$1.71M
KYNB
42
PUT
Kyntra Bio
KYNB
$28.5M
$1.75M 0.11%
+26,000
New +$10.8M
KYNB
43
Kyntra Bio
KYNB
$28.5M
$1.72M 0.11%
+25,503
New +$10.5M
PDSB icon
44
PDS Biotechnology
PDSB
$38.1M
$717K 0.05%
142,635
– –
KYNB
45
CALL
Kyntra Bio
KYNB
$28.5M
$675K 0.04%
+10,000
New +$4.14M
FUSN
46
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$547K 0.04%
117,099
– –
SVRA icon
47
Savara
SVRA
$1.13B
$308K 0.02%
+96,248
New +$226K
ALLK
48
DELISTED
Allakos
ALLK
$272K 0.02%
+62,465
New +$281K
SYBX
49
DELISTED
Synlogic
SYBX
$247K 0.02%
38,331
– –
MIRM icon
50
Mirum Pharmaceuticals
MIRM
$6.89B
$235K 0.02%
+9,089
New +$242K
1
2
3

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q2 2023 Portfolio in Review

As of Q2 2023, Sofinnova Investments held 69 positions worth $1.53B, down 2.4% from $1.56B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Sofinnova Investments withdrew a net $162M in Q2 2023, closing 17 positions and reducing 13 holdings. Its most notable exit was Eli Lilly, an estimated $47.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 94% a quarter earlier.

Against the trend, Sofinnova Investments opened a new position in AstraZeneca worth $121M.

  • Sofinnova Investments's largest Q2 2023 buy was AstraZeneca: 848,759 shares worth $121M.
  • Sofinnova Investments added most to Exelixis in Q2 2023, an estimated $33.3M increase.
  • Sofinnova Investments's biggest Q2 2023 reduction was Karuna Therapeutics, Inc. Common Stock, cutting an estimated $84M.
  • Sofinnova Investments fully exited Eli Lilly in Q2 2023, selling an estimated $47.1M.
  • Sofinnova Investments's ten largest holdings make up 65% of its $1.53B portfolio in Q2 2023.
  • Sofinnova Investments opened 17 new positions and closed 17 in Q2 2023.
  • Sofinnova Investments's portfolio value fell 2.4% quarter-over-quarter to $1.53B.

Based on Sofinnova Investments's 13F filing for Q2 2023, filed 14 Aug 2023.